Ablavar is a brand name of gadofosveset trisodium, approved by the FDA in the following formulation(s):
ABLAVAR (gadofosveset trisodium - solution; intravenous)
Manufacturer: LANTHEUS MEDCL
Approval date: December 22, 2008
Strength(s): 2440MG/10ML (244MG/ML), 3660MG/15ML (244MG/ML) [RLD]
Has a generic version of Ablavar been approved?
No. There is currently no therapeutically equivalent version of Ablavar available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ablavar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Gadolinium chelates for magnetic resonance imaging
Patent 5,362,475
Issued: November 8, 1994
Inventor(s): Gries; Heinz & Rosenberg; Douwe & Weinmann; Hanns-Joachim & Speck; Ulrich & Mutzel; Wolfgang & Hoyer; Georg-Alexander & Pfeiffer, deceased; Heinrich & Renneke; Franz-Josef
Assignee(s): Schering Aktiengesellschaft
A diagnostic medium contains at least one physiologically well tolerated complex salt comprising an anion of a complexing acid and one or more Gadolinium ions and, optionally, one or more physiologically biocompatible cation or cations of an inorganic and/or organic base or amino acid, optionally, with additives customary in galenic formulations, dissolved or suspended in an aqueous medium.Patent expiration dates:
- November 8, 2011✓
- November 8, 2011
Diagnostic imaging contrast agents with extended blood retention
Patent 6,676,929
Issued: January 13, 2004
Inventor(s): Thomas J.; McMurry & Hironao; Sijiki & Daniel M.; Scott & Randall B.; Lauffer
Assignee(s): Epix Medical, Inc.
The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Patent expiration dates:
- May 26, 2015✓
- May 26, 2015
Diagnostic imaging contrast agents with extended blood retention
Patent 7,011,815
Issued: March 14, 2006
Inventor(s): McMurry; Thomas J. & Sijiki; Hironao & Scott; Daniel M. & Lauffer; Randall B.
Assignee(s): Epix Pharmaceuticals, Inc.
The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Patent expiration dates:
- February 1, 2015✓
- February 1, 2015
Diagnostic imaging contrast agents with extended blood retention
Patent 7,060,250
Issued: June 13, 2006
Inventor(s): McMurry; Thomas J. & Sijiki; Hironao & Scott; Daniel M. & Lauffer; Randall B.
Assignee(s): Epix Pharmaceuticals, Inc.
The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Patent expiration dates:
- May 26, 2015✓
- May 26, 2015
Diagnostic imaging contrast agents with extended blood retention
Patent 7,229,606
Issued: June 12, 2007
Inventor(s): McMurry; Thomas J. & Sijiki; Hironao & Scott; Daniel M. & Lauffer; Randall B.
Assignee(s): Epix Pharmaceuticals, Inc.
The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Patent expiration dates:
- May 26, 2015✓
- May 26, 2015
Diagnostic imaging contrast agents with extended blood retention
Patent 8,017,105
Issued: September 13, 2011
Inventor(s): McMurry; Thomas J. & Sijiki; Hironao & Scott; Daniel M. & Lauffer; Randall B.
Assignee(s): Lantheus Medical Imaging, Inc.
The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Patent expiration dates:
- May 26, 2015✓
- May 26, 2015
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- December 22, 2013 - NEW CHEMICAL ENTITY
See also...
- Ablavar Consumer Information (Cerner Multum)
- Ablavar Advanced Consumer Information (Micromedex)
- Gadofosveset trisodium Consumer Information (Cerner Multum)
- Gadofosveset Injection Advanced Consumer Information (Micromedex)
No comments:
Post a Comment